Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Geneva, Switzerland and Boston, MA - May 11, 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will report financial results for the first quarter ended March 31, 2017 on Thursday, May 18, 2017. ObsEva will host an investment community conference call at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time) on May 18, 2017 to discuss the financial results and provide a corporate update.
Investors may participate in the conference call by dialing 844-419-1772 for U.S. callers and (213) 660-0921 for international callers, with conference ID: 21002537.
Those interested in listening to the conference call live via the internet may do so by visiting the "Investors" page of ObsEva's website at www.obseva.com and clicking on the webcast link.
A webcast replay of the conference call will be available on the "Investors" page of ObsEva's website at www.obseva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
Investor Contact:
Mario Corso
Senior Director, Investor Relations
[email protected]
781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/0f853e1e-9419-4a3b-85af-60e6f96631b6
